Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. (Q48342806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

title

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Jean-Mathieu Beauregard

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

François-Alexandre Buteau

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

31 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

number of pages

11

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

1490-1500

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-017-3688-2

14 March 2020

exact match

0 references

cites work

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Long-term results of PRRT in advanced bronchopulmonary carcinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3688-2

Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy

21 January 2018

1 reference

12 December 2020

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

1 reference

12 December 2020

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

12 December 2020

Tolerance of normal tissue to therapeutic irradiation

1 reference

12 December 2020

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

1 reference

12 December 2020

Minor changes in effective half-life during fractionated 177Lu-octreotate therapy

1 reference

12 December 2020

10.1007/S00259-017-3688-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28361189%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference